Protease inhibitor: Roche lottery deadline July 21.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D001315:Australia; D018791:CD4 Lymphocyte Count; D002170:Canada; D004345:Drug Industry; D004352:Drug Resistance, Microbial; D005060:Europe; D017320:HIV Protease Inhibitors / Q000600:supply & distribution* / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir; D007546:Isoquinolines / Q000600:supply & distribution* / Q000627:therapeutic use; D018579:Patient Selection; D011725:Pyridines / Q000600:supply & distribution / Q000627:therapeutic use; D011804:Quinolines / Q000600:supply & distribution* / Q000627:therapeutic use; D019258:Saquinavir; D014481:United States
D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011725:Pyridines; D011804:Quinolines; D019469:Indinavir; D019258:Saquinavir